The FDA has approved Eylea HD (aflibercept) 8 mg to treat patients with macular edema following retinal vein occlusion (RVO) with dosing of up to every 8 weeks after an initial monthly dosing period.

Dublin, Aug. 19, 2025 (GLOBE NEWSWIRE) -- The "Structural Heart Occlusion Devices Market by Product Type (Atrial Septal Defect Devices, Patent Foramen Ovale Devices, Ventricular Septal Defect Devices) ...

The global Retinal Vein Occlusion Treatment market is expected to be valued US$ 2.3 billion in 2023, with a compound annual growth rate (CAGR) of 5.9% from 2023 to 2033, reaching US$ 4.7 billion. One ...

CRVO occurs when blood can no longer travel through the main blood vessel that brings blood to the back of the eye. This can cause swelling, and it may lead to vision loss. The retina is a layer of ...

Retrospective chart review of all patients evaluated over a 4-year period in a tertiary diabetes eye care center. Ophthalmic findings were recorded including visual acuity and the presence of retinal ...

Chronic total occlusion catheters are used for treating total blockages of coronary arteries. Chronic total occlusions are of two types consisting of hard plaques and soft plaques. Treatment for ...

"Retinal Vein Occlusion Drugs Market"Retinal Vein Occlusion companies include Regeneron Pharmaceuticals, Kodiak Sciences Inc, Chugai Pharmaceuticals, Aerie Pharmaceuticals, Roche, Graybug Vision, ...

A 35-year-old Chinese man suffered permanent vision impairment in his right eye after an all-night gaming session led to a sudden central retinal artery occlusion, commonly known as an "eye stroke." ...

(MENAFN- GlobeNewsWire - Nasdaq) The structural heart occlusion device market offers opportunities driven by innovations in device design, biomaterials, and minimally invasive interventions. Surge in ...